Breaking News Instant updates and real-time market news.

ALXN

Alexion

$118.24

0.68 (0.58%)

07:31
06/14/18
06/14
07:31
06/14/18
07:31

Alexion to present results from ALXN1210 Phase 3 study at EHA

Alexion Pharmaceuticals announced that results from one of the two large Phase 3 studies of ALXN1210, the company's investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria were selected for presentation during the Late-Breaking Oral Session on Sunday, June 17, 2018 at the Annual Conference of the European Hematology Association in Stockholm, Sweden. "We are very excited about EHA's recognition of the robustness and importance of these data in complement inhibitor treatment-naive patients. We enrolled a very broad patient population, representative of patients with PNH in clinical practice, including patients with a history of aplastic anemia, and 'classic' PNH, as well as transfused and non-transfused patients," said John Orloff, M.D., EVP and Head of Research & Development at Alexion. "We look forward to discussing the data with leading hematologists in Europe at the conference later this week as part of our ambition to make ALXN1210 the new standard of care for patients with PNH." As previously announced, weight-optimized treatment every eight weeks with ALXN1210 demonstrated non-inferiority to treatment every two weeks with Soliris in complement inhibitor treatment-naive patients with PNH on the two co-primary endpoints and all four key secondary endpoints. The numeric results for all these endpoints, including breakthrough hemolysis, favored ALXN1210 and are consistent with the immediate and complete C5 inhibition observed by the end of the first infusion of ALXN1210 and sustained throughout the entire 26-week treatment period. The safety profile of ALXN1210, based on almost 180 patient years of experience, was similar to that of Soliris.

ALXN Alexion
$118.24

0.68 (0.58%)

05/08/18
JEFF
05/08/18
NO CHANGE
JEFF
Hold
Alexion CoM patent for Soliris rejected by European regulator, says Jefferies
Jefferies analyst Eun Yang reported that the European Patent Office's Examining Division issued a rejection to Alexion's new Composition of Matter, or CoM, patent application for Soliris. If one is not issued, a potential biosimilar entry is likely in about 2020 in the EU, added Yang, who noted that the company has requested oral proceedings, which are set to take place in February 2019. The analyst has a Hold rating on Alexion.
05/08/18
EVER
05/08/18
NO CHANGE
Target $150
EVER
Outperform
Alexion EU patent not 'a need to have,' says Evercore ISI
Evercore ISI analyst Josh Schimmer notes Alexion is trading lower after an announcement that the European Patent Office rejected a new composition of matter patent for Soliris which could extended to 2027. The analyst points out that this patent was never part of his investment thesis, as he views it more as a "nice to have" rather than a "need to have" for success given many additional barriers to entry including label expansions and raising the bar through Q8W 1210 IV and ultimately s.c. dosing. Schimmer reiterates an Outperform rating and $150 price target on the shares. In afternoon trading, shares of Alexion have dropped over 4% to $113.23.
05/08/18
PIPR
05/08/18
NO CHANGE
Target $170
PIPR
Overweight
Alexion should be bought on weakness, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says he would be a buyer of Alexion's shares on weakness today as he thinks the market's reaction to what really amounts to "nothing more than a procedural update" from the EPO is "wholly misplaced." The analyst reminds investors that the Soliris composition of matter patent in question already was subject to a first office action rejection in November of last year. This recent news reflects a continuation of that back and forth, and the real revelation on this does not occur till the oral hearing next February, he adds. Raymond reiterates an Overweight rating and $170 price target on the shares.
06/05/18
FBCO
06/05/18
NO CHANGE
Target $154
FBCO
Outperform
Alexion price target raised to $154 from $149 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Alexion to $154 from $149 saying the resolution of overhangs on the shares supports upside, namely if a global 1210 switch strategy is viable given Soliris EU IP uncertainty and what will drive long-term growth for Alexion. The analyst expects partial or full resolution of the first overhang as investors recognize that biosimilar risk may largely be limited to the PNH indication, and lackluster competitive C5 data and probable biosimilar pushouts suggest bearish timeline assumptions are low risk, likely allowing ample time to convert the market to 1210 from Soliris. Auster reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

IBTX

Independent Bank

$67.05

(0.00%)

, GBNK

Guaranty Bancorp

$29.95

(0.00%)

14:25
09/25/18
09/25
14:25
09/25/18
14:25
Conference/Events
Guaranty Bancorp to host special shareholder meeting »

Special Shareholder…

IBTX

Independent Bank

$67.05

(0.00%)

GBNK

Guaranty Bancorp

$29.95

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

14:20
09/25/18
09/25
14:20
09/25/18
14:20
General news
FOMC began its 2-day meeting and will announce its decision at 14 ET Wednesday »

FOMC began its 2-day…

CRM

Salesforce

$158.62

-0.235 (-0.15%)

, AAPL

Apple

$222.01

1.22 (0.55%)

14:19
09/25/18
09/25
14:19
09/25/18
14:19
Hot Stocks
Salesforce Co-CEO Benioff says 'economy is still ripping' »

Marc Benioff is being…

CRM

Salesforce

$158.62

-0.235 (-0.15%)

AAPL

Apple

$222.01

1.22 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/25/18
09/25
14:17
09/25/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/25/18
09/25
14:16
09/25/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRS

Antares Pharma

$3.47

0.175 (5.31%)

14:10
09/25/18
09/25
14:10
09/25/18
14:10
Options
5-strike call buyers in Antares Pharma and implied volatility spikes »

5-strike call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

FB

Facebook

$165.12

-0.285 (-0.17%)

14:06
09/25/18
09/25
14:06
09/25/18
14:06
Periodicals
Facebook likely to pick Adam Mosseri to head Instagram, The Information says »

Facebook will likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 07

    Nov

PAYX

Paychex

$73.06

-1.5 (-2.01%)

, ADP

ADP

$147.62

-1.5 (-1.01%)

14:04
09/25/18
09/25
14:04
09/25/18
14:04
Recommendations
Paychex, ADP, Square analyst commentary  »

New Square payroll app…

PAYX

Paychex

$73.06

-1.5 (-2.01%)

ADP

ADP

$147.62

-1.5 (-1.01%)

SQ

Square

$94.22

8.16 (9.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 11

    Oct

  • 22

    Oct

  • 31

    Oct

  • 26

    Nov

NTES

NetEase

$214.55

4.41 (2.10%)

14:00
09/25/18
09/25
14:00
09/25/18
14:00
Upgrade
NetEase rating change  »

Follow-up: NetEase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$147.41

-1.71 (-1.15%)

13:55
09/25/18
09/25
13:55
09/25/18
13:55
Options
ADP put volume heavy and directionally bearish »

Bearish flow noted in ADP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 31

    Oct

GTS

Triple-S

$20.33

-0.7 (-3.33%)

13:50
09/25/18
09/25
13:50
09/25/18
13:50
Hot Stocks
Triple-S finalizes contract with Government of Puerto Rico on Medicaid plan »

Triple-S Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NTES

NetEase

$214.61

4.47 (2.13%)

13:47
09/25/18
09/25
13:47
09/25/18
13:47
Upgrade
NetEase rating change  »

NetEase upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$182.29

5.41 (3.06%)

, GOOG

Alphabet

$1,184.00

10.62 (0.91%)

13:46
09/25/18
09/25
13:46
09/25/18
13:46
Periodicals
Spotify asks EU for stronger regulations against U.S. rivals, Reuters reports »

Driven by concerns over…

SPOT

Spotify

$182.29

5.41 (3.06%)

GOOG

Alphabet

$1,184.00

10.62 (0.91%)

GOOGL

Alphabet Class A

$1,192.91

13.13 (1.11%)

AMZN

Amazon.com

$1,957.44

22.94 (1.19%)

EBAY

eBay

$32.72

-1 (-2.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

HIMX

Himax

$5.87

-0.03 (-0.51%)

13:45
09/25/18
09/25
13:45
09/25/18
13:45
Options
Himax call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
09/25/18
09/25
13:45
09/25/18
13:45
General news
FOMC Forecast revisions »

FOMC Forecast revisions…

SHOP

Shopify

$163.33

1.06 (0.65%)

, AMZN

Amazon.com

$1,957.00

22.5 (1.16%)

13:43
09/25/18
09/25
13:43
09/25/18
13:43
Periodicals
Shopify CEO welcomes competition from Amazon, Bloomberg reports »

Shopify's (SHOP) CEO…

SHOP

Shopify

$163.33

1.06 (0.65%)

AMZN

Amazon.com

$1,957.00

22.5 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 13

    Nov

CHRS

Coherus Biosciences

$16.35

0.3 (1.87%)

13:40
09/25/18
09/25
13:40
09/25/18
13:40
Hot Stocks
Coherus Biosciences receives European Commission approval for UDENYCA »

Coherus BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 03

    Nov

LMT

Lockheed Martin

$344.92

7.27 (2.15%)

13:36
09/25/18
09/25
13:36
09/25/18
13:36
Hot Stocks
U.S. Army awards Lockheed Martin $289M HIMARS contract »

The U.S. Army awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

KMX

CarMax

$76.31

0.43 (0.57%)

13:35
09/25/18
09/25
13:35
09/25/18
13:35
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 06

    Nov

NKE

Nike

$84.97

0.7 (0.83%)

, CTAS

Cintas

$211.87

0.69 (0.33%)

13:35
09/25/18
09/25
13:35
09/25/18
13:35
Earnings
Notable companies reporting after market close »

Notable companies…

NKE

Nike

$84.97

0.7 (0.83%)

CTAS

Cintas

$211.87

0.69 (0.33%)

KBH

KB Home

$25.53

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

JBL

Jabil

$27.43

-2.65 (-8.81%)

, CLS

Celestica

$10.72

-0.14 (-1.29%)

13:35
09/25/18
09/25
13:35
09/25/18
13:35
Hot Stocks
Jabil falls after CEO commentary on margin and expansion, peers also fall »

Shares of companies…

JBL

Jabil

$27.43

-2.65 (-8.81%)

CLS

Celestica

$10.72

-0.14 (-1.29%)

SANM

Sanmina

$28.40

-0.9 (-3.07%)

FLEX

Flex

$12.97

-0.33 (-2.48%)

XLNX

Xilinx

$77.89

-1.26 (-1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 01

    Oct

  • 09

    Oct

  • 13

    Nov

13:32
09/25/18
09/25
13:32
09/25/18
13:32
Conference/Events
JPMorgan Euro software analysts to hold an analyst/industry conference call »

European Software &…

T

AT&T

$33.95

0.04 (0.12%)

13:31
09/25/18
09/25
13:31
09/25/18
13:31
Periodicals
AT&T CEO wants more HBO content over next three years, Variety reports »

AT&T CEO Randall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 21

    Oct

  • 24

    Oct

  • 06

    Nov

  • 12

    Nov

XLV

Health Care Select Sector SPDR

$94.41

-0.01 (-0.01%)

13:30
09/25/18
09/25
13:30
09/25/18
13:30
Options
Large hedge in the SPDR Healthcare Fund »

Large hedge in the SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$94.08

0.64 (0.68%)

, VRTX

Vertex

$182.97

0.69 (0.38%)

13:26
09/25/18
09/25
13:26
09/25/18
13:26
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts Xu,…

ABBV

AbbVie

$94.08

0.64 (0.68%)

VRTX

Vertex

$182.97

0.69 (0.38%)

ACER

Acer Therapeutics

$30.56

0.86 (2.90%)

BHVN

Biohaven Pharmaceutical

$36.71

0.37 (1.02%)

CELG

Celgene

$88.17

0.6 (0.69%)

EXEL

Exelixis

$17.11

0.24 (1.42%)

PTLA

Portola Pharmaceuticals

$27.54

0.38 (1.40%)

BMY

Bristol-Myers

$62.23

0.65 (1.06%)

BIIB

Biogen

$344.09

-2.89 (-0.83%)

AMGN

Amgen

$207.98

0.68 (0.33%)

BLUE

Bluebird Bio

$142.65

3.1 (2.22%)

ONCE

Spark Therapeutics

$56.21

0.19 (0.34%)

LOXO

Loxo Oncology

$163.72

0.65 (0.40%)

RCKT

Rocket Pharmaceuticals

$25.44

0.67 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 01

    Oct

  • 03

    Oct

  • 04

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 09

    Nov

  • 26

    Nov

  • 27

    Nov

  • 01

    Dec

  • 31

    Dec

  • 14

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.